With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is 1 987,57 ₴, with a 24-hour trading volume of 18,9B ₴. The asset's market cap is 8,8T ₴, after moving 1.28% in the last day.
Tokenized Novo Nordisk A/S is trading at 2 032,12 ₴, with a tokenized market cap of 162,15M ₴ and a 24-hour trading volume of 46,98M ₴. The tokenized asset has moved 1.19% in the past 24 hours.